Interim Report 2026
Filed with HKEX · Stock code 1652 · · 47 pages · English
Corporate Information 2 Chairman’s Statement 4 Management Discussion and Analysis 5 Disclosure of Interests 11 Corporate Governance and Other Information 17 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 20 Condensed Consolidated Statement of Financial Position 22 Condensed Consolidated Statement of Changes in Equity 24 Condensed Consolidated Statement of Cash Fl
Fusen Pharmaceutical Co., Ltd. on 6ix
Earlier from Fusen Pharmaceutical
- Fusen Pharmaceutical: Proposals for general mandates to issue shares and repurchase shares, re-election of directors, re-appointment of auditors, declaration of final dividend, amendments to the memorandum and the articles, adoption of the amended and restated memorandum and articles of association and notice of annual general meeting
- Appointment of independent non-executive director
Later from Fusen Pharmaceutical
- Notification Letter to Registered Shareholders and Reply Form - Notice of Publication of Interim Report
- Notification Letter to Non-Registered Holders and Reply Form - Notice of Publication of Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Further extension of completion date of major transaction in relation to deemed disposal of equity interest in henan Fusen Pharmaceutical company limited
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Fusen Pharmaceutical into a list and get an email when it puts out news.
Follow Fusen Pharmaceutical